Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Adcetris

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

Eli Lilly HQ

Pfizer and Lilly restart tanezumab pain trials

FDAlifts clinical block on late-stage studies of the novel painkiller

- PMLiVE

NICE gives nod to blood cancer drug Gazyvaro

Roche’s leukaemia drug to be used in combination with chemotherapy

- PMLiVE

NICE recommends BMS and Pfizer’s Eliquis for blood clots

Will be a treatment option for venous thromboembolism

- PMLiVE

Novartis and GSK complete oncology and vaccines swap

Follows Swiss company's decision to divest its BRAF and MEK inhibitors to Array BioPharma

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

National Institute for Health and Care Excellence NICE logo

Good NICE news for Pfizer, but Dendreon drug rejected

Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not

- PMLiVE

Merck takes promotional responsibility for Erbitux in Japan

Currently co-promotes the drug withBristol-Myers Squibb

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

- PMLiVE

Early win for Pfizer as Remicade biosimilar launches in West Europe

Hospira launchescopycat version of Janssen/MSD’s drug in major European markets

EISAI

Eisai given early approval for new oncology drug

Japanese firm’s thyroid cancer treatment Lenvimaset to be a blockbuster

- PMLiVE

Pfizer UK appoints Erik Nordkamp as new managing director

He takes over from Jonathan Emms who moves to a global role within the firm

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links